论文部分内容阅读
本文目的是估价抗真菌药氟康唑(fluconazole)对已完成有效的初期抗隐球菌脑膜炎治疗的艾滋病患者维持治疗的效果。对象和方法:美国三所大学附属医学中心和一个私人医学团体进行的随机、双盲、安慰剂对照实验,实验天数13～529天,平均140天。所选病人为已证明感染HIV并在近4个月内诊断患隐球菌脑膜炎的成年患者,这些患者近3周曾接受两性霉素B或两性霉素B加氟胞嘧啶系统标准疗程的治疗。对咪唑不耐受,有中度肝功能异常,血清肌肝>190μmol/L,妊娠或正在接受全身或椎管内抗真菌治疗者未包括在内。将61例病人随机分组,第一阶段病人每天服氟康唑100mg,或安慰剂共3个月,第二阶段每天服氟康唑200
The purpose of this article is to evaluate the efficacy of the antifungal fluconazole in maintenance treatment of AIDS patients who have completed effective primary anti-cryptococcal meningitis treatment. Subjects and Methods: A randomized, double-blind, placebo-controlled trial conducted by the Affiliated Medical Centers of the three U.S. universities and a private medical community for 13 to 529 days with an average of 140 days. The patients selected were adult patients who had contracted HIV and had been diagnosed with cryptococcal meningitis in the recent 4 months and who had received standard treatment with amphotericin B or amphotericin B plus fluorocytosine for approximately 3 weeks . Imidazole intolerance, with moderate liver dysfunction, serum muscle liver> 190μmol / L, pregnancy or are undergoing systemic or intraspinal antifungal therapy were not included. Sixty-one patients were randomized to receive either fluconazole 100 mg or placebo for three months in the first phase, and fluconazole 200